Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 6/20 | 0.84 |
| ▸ | PTGS2 | P35354 | 6/20 | 0.84 |
| ▸ | MAPT | P10636 | 5/20 | 0.84 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.84 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.84 |
| ▸ | LMNA | P02545 | 3/20 | 0.84 |
| ▸ | CXCR1 | P25024 | 2/20 | 0.84 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.84 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.84 |
| ▸ | RECQL | P46063 | 1/20 | 0.84 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.84 |
| ▸ | HPGD | P15428 | 1/20 | 0.84 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.84 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.84 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.84 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.84 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.84 |
| ▸ | THPO | P40225 | 1/20 | 0.84 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.84 |
| ▸ | HTT | P42858 | 3/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4465718 | 1.00 | PTGS1 (0.84) | PTGS1PTGS2MAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL4485618 | 1.00 | PTGS1 (0.84) | PTGS1PTGS2MAPTSMN1; SMN2ALDH1A1 | |
| Ketoprofen SCHEMBL28602451 | 0.92 | PTGS1 (0.93) | PTGS1PTGS2MAPTSMN1; SMN2ALDH1A1 | |
| Dexketoprofen SCHEMBL66987 | 0.91 | PTGS1 (1.00) | PTGS1PTGS2MAPTSMN1; SMN2ALDH1A1 | |
| Ketoprofen SCHEMBL16757741 | 0.91 | PTGS1 (1.00) | PTGS1PTGS2MAPTSMN1; SMN2ALDH1A1 | |
| R-Ketoprofen SCHEMBL29353694 | 0.91 | PTGS1 (1.00) | PTGS1PTGS2MAPTSMN1; SMN2ALDH1A1 | |
| Dexketoprofen SCHEMBL29396875 | 0.91 | PTGS1 (1.00) | PTGS1PTGS2MAPTSMN1; SMN2ALDH1A1 | |
| Ketoprofen SCHEMBL8754790 | 0.91 | PTGS1 (1.00) | PTGS1PTGS2MAPTSMN1; SMN2ALDH1A1 | |
| Ketoprofen SCHEMBL8577572 | 0.91 | PTGS1 (1.00) | PTGS1PTGS2MAPTSMN1; SMN2ALDH1A1 | |
| Ketoprofen SCHEMBL3843886 | 0.91 | PTGS1 (1.00) | PTGS1PTGS2MAPTSMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1581474-B1 | CHIRAL ARYLKETONES IN THE TREATEMENT OF NEUTROPHIL-DEPENDENT INFLAMMATORY DESEASES | DOMPE SPA (IT) | 2008-08-27 | — | — | EP | claimed |
| JP-56097249-A | — | — | None | — | — | JP | disclosed |
| US-20240016799-A1 | ANTI-INFLAMMATORY, ANTI-CANCER, AND ANTI-ANGIOGENIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF MAKING AND USING THEREOF | MEDICON PHARMACEUTICALS, INC. | 2024-01-18 | — | — | US | disclosed |
| EP-4272761-A2 | COMPOSITIONS FOR TREATING OPHTHALMIC CONDITIONS | Medicon Pharmaceuticals, Inc. (US) | 2023-11-08 | — | — | EP | disclosed |
| US-20230293557-A1 | COMPOSITIONS AND METHODS FOR TREATING OPHTHALMIC CONDITIONS | MEDICON PHARMACEUTICALS INC (US) | 2023-09-21 | — | — | US | disclosed |
| US-20230293557-A1 | COMPOSITIONS AND METHODS FOR TREATING OPHTHALMIC CONDITIONS | MEDICON PHARMACEUTICALS INC (US) | 2023-09-21 | — | — | US | disclosed |
| US-11752146-B2 | Anti-inflammatory, anti-cancer, and anti-angiogenic compounds, pharmaceutical compositions, and methods of making and using thereof | MEDICON PHARMACEUTICALS, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| EP-4238571-A1 | APPLICATION OF THYMIDINE DERIVATIVE IN PREPARATION OF DRUGS | OnQuality Pharmaceuticals China Ltd. (CN) | 2023-09-06 | — | — | EP | disclosed |
| US-20230157952-A1 | METHOD FOR IMPROVING THE STABILITY OF A PHARMACEUTICAL COMPOSITION COMPRISING A HIGH PENETRATION DRUG, AND THE PHARMACEUTICAL COMPOSITION OBTAINED THEREFROM | TECHFIELDS INC. (US) | 2023-05-25 | — | — | US | disclosed |
| US-20200246330-A1 | ANTI-INFLAMMATORY, ANTI-CANCER, AND ANTI-ANGIOGENIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF MAKING AND USING THEREOF | MEDICON PHARMACEUTICALS, INC. (US) | 2020-08-06 | — | — | US | disclosed |
| US-20090203652-A1 | CHIRAL ARYLKETONES IN THE TREATMENT OF NEUTROPHIL-DEPENDENT INFLAMMATORY DISEASES | DOMPE PHA.R.MA S.P.A. (IT) | 2009-08-13 | — | — | US | disclosed |
| US-20090093510-A1 | Use of Nitrooxyderivatives of Drug for the Treatment of Muscular Dystrophies | NICOX SA (FR) | 2009-04-09 | — | — | US | disclosed |
| US-20090076174-A1 | CONTROL RELEASE OF BIOLOGICALLY ACTIVE COMPOUNDS FROM MULTI-ARMED OLIGOMERS | BEZWADA BIOMEDICAL, LLC (US) | 2009-03-19 | — | — | US | disclosed |
| US-7491730-B2 | Compositions useful as inhibitors of GSK-3 | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-02-17 | — | — | US | disclosed |
| EP-1581474-B1 | CHIRAL ARYLKETONES IN THE TREATEMENT OF NEUTROPHIL-DEPENDENT INFLAMMATORY DESEASES | DOMPE SPA (IT) | 2008-08-27 | — | — | EP | disclosed |
| WO-2007088123-A2 | USE OF NITROOXYDERIVATIVE OF DRUG FOR THE TREATMENT OF MUSCULAR DYSTROPHIES | NICOX S.A. (FR) | 2007-08-09 | — | — | WO | disclosed |
| US-20060247297-A1 | Chiral arylketones in the treatment of neutrophil-dependent inflammatory diseases | DOMPE PHA.R.MA S.P.A. (IT) | 2006-11-02 | — | — | US | disclosed |
| EP-1581474-A1 | CHIRAL ARYLKETONES IN THE TREATEMENT OF NEUTROPHIL-DEPENDENT INFLAMMATORY DESEASES | Dompé S.P.A. (IT) | 2005-10-05 | — | — | EP | disclosed |
| WO-2004052830-A1 | CHIRAL ARYLKETONES IN THE TREATEMENT OF NEUTROPHIL-DEPENDENT INFLAMMATORY DESEASES | DOMPE S.P.A. (IT) | 2004-06-24 | — | — | WO | disclosed |
| JP-S5697249-A | PREPARATION OF 2-ARYLALKANE ACID | OTA SEIYAKU KK | 1981-08-05 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090076174-A1 | CONTROL RELEASE OF BIOLOGICALLY ACTIVE COMPOUNDS FROM MULTI-ARMED OLIGOMERS | MME, CTSA, ALG1 | PTGS1 3338/4885PTGS2 3821/4885MAPT 869/4885 |
| US-20230293557-A1 | COMPOSITIONS AND METHODS FOR TREATING OPHTHALMIC CONDITIONS | PDE6C, PDE6H, PDE6D | PTGS1 137/4885PTGS2 101/4885MAPT 924/4885 |
| US-20060247297-A1 | Chiral arylketones in the treatment of neutrophil-dependent inflammatory diseases | NR1H4, MMP8, NR1I2 | PTGS1 664/4885PTGS2 803/4885MAPT 1794/4885 |
| US-20200246330-A1 | ANTI-INFLAMMATORY, ANTI-CANCER, AND ANTI-ANGIOGENIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF MAKING AND USING THEREOF | VEGFA, HPGDS, ALOX5 | PTGS1 9/4885PTGS2 18/4885MAPT 1504/4885 |
| US-11752146-B2 | Anti-inflammatory, anti-cancer, and anti-angiogenic compounds, pharmaceutical compositions, and methods of making and using thereof | VEGFA, HPGDS, ALOX5 | PTGS1 9/4885PTGS2 18/4885MAPT 1504/4885 |
| US-20240016799-A1 | ANTI-INFLAMMATORY, ANTI-CANCER, AND ANTI-ANGIOGENIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF MAKING AND USING THEREOF | VEGFA, HPGDS, ALOX5 | PTGS1 9/4885PTGS2 18/4885MAPT 1504/4885 |
| US-20230157952-A1 | METHOD FOR IMPROVING THE STABILITY OF A PHARMACEUTICAL COMPOSITION COMPRISING A HIGH PENETRATION DRUG, AND THE PHARMACEUTICAL COMPOSITION OBTAINED THEREFROM | SLC7A1, ABCG2, SLCO4C1 | PTGS1 707/4885PTGS2 619/4885MAPT 602/4885 |
| US-20090203652-A1 | CHIRAL ARYLKETONES IN THE TREATMENT OF NEUTROPHIL-DEPENDENT INFLAMMATORY DISEASES | NR1H4, MMP8, NR1I2 | PTGS1 664/4885PTGS2 803/4885MAPT 1794/4885 |
| US-20090093510-A1 | Use of Nitrooxyderivatives of Drug for the Treatment of Muscular Dystrophies | TNNC1, CPT1B, SMN1; SMN2 | PTGS1 292/4885PTGS2 440/4885MAPT 2656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.